Abstract 3840: ATF3 drives synergy between protein disulfide isomerase (PDI) inhibitors and epigenetic cancer therapy

Volume: 79, Pages: 3840 - 3840
Published: Jul 1, 2019
Abstract
The clinical potential of epigenetic cancer therapy has not been fully realized. Histone deacetylase inhibitors (HDACi), for example, only benefit a minor fraction of all cancer patients despite thousands of preclinical studies demonstrating their antitumor effects. In this study we show that a new structural class of protein disulfide isomerase (PDI) that was discovered by our lab dramatically enhances the antitumor effects of HDACi and select...
Paper Details
Title
Abstract 3840: ATF3 drives synergy between protein disulfide isomerase (PDI) inhibitors and epigenetic cancer therapy
Published Date
Jul 1, 2019
Volume
79
Pages
3840 - 3840
Citation AnalysisPro
  • Scinapse’s Top 10 Citation Journals & Affiliations graph reveals the quality and authenticity of citations received by a paper.
  • Discover whether citations have been inflated due to self-citations, or if citations include institutional bias.